Publications by authors named "Evan E Gross"
Background: The optimal treatment for metastatic renal cell carcinoma (mRCC) patients who have progressed after both immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) remains uncertain. Lenvatinib and everolimus (LE) are frequently used in combination as salvage therapy because of their different antitumor mechanisms, but efficacy and toxicity data in this setting are lacking.
Methods: We retrospectively reviewed charts from two academic centers for 71 adult mRCC patients who received LE after prior ICI and TKI exposure.
Article Synopsis
- A study looked at a surgery called cytoreductive nephrectomy (CN) for patients with advanced kidney cancer who received immunotherapy and wanted to see how it affects their survival.
- The research included 367 patients, and those who had CN along with immunotherapy lived longer (about 56.3 months) compared to those who only had immunotherapy (about 19.1 months).
- The results suggest that CN can help patients with metastatic kidney cancer live longer when combined with immunotherapy, so doctors might consider it for some patients.